BRPI0907584A2 - Composto e composições como moduladores de atividade de gpr119 - Google Patents
Composto e composições como moduladores de atividade de gpr119Info
- Publication number
- BRPI0907584A2 BRPI0907584A2 BRPI0907584-4A BRPI0907584A BRPI0907584A2 BR PI0907584 A2 BRPI0907584 A2 BR PI0907584A2 BR PI0907584 A BRPI0907584 A BR PI0907584A BR PI0907584 A2 BRPI0907584 A2 BR PI0907584A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- compound
- activity modulators
- gpr119 activity
- gpr119
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3090708P | 2008-02-22 | 2008-02-22 | |
PCT/US2009/034781 WO2009105715A1 (en) | 2008-02-22 | 2009-02-20 | Compounds and compositions as modulators of gpr119 activity |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0907584A2 true BRPI0907584A2 (pt) | 2015-07-21 |
Family
ID=40512579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0907584-4A BRPI0907584A2 (pt) | 2008-02-22 | 2009-02-20 | Composto e composições como moduladores de atividade de gpr119 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20110166176A1 (pt) |
EP (1) | EP2262496A1 (pt) |
JP (1) | JP2011513232A (pt) |
KR (1) | KR20100120689A (pt) |
CN (1) | CN102006870A (pt) |
AU (1) | AU2009217359B2 (pt) |
BR (1) | BRPI0907584A2 (pt) |
CA (1) | CA2714703A1 (pt) |
EA (1) | EA201001332A1 (pt) |
MX (1) | MX2010009204A (pt) |
WO (1) | WO2009105715A1 (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010264720A1 (en) | 2009-06-24 | 2011-12-08 | Boehringer Ingelheim International Gmbh | New compounds, pharmaceutical composition and methods relating thereto |
WO2010149685A1 (en) | 2009-06-24 | 2010-12-29 | Boehringer Ingelheim International Gmbh | New compounds, pharmaceutical composition and methods relating thereto |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US20130109703A1 (en) | 2010-03-18 | 2013-05-02 | Boehringer Ingelheim International Gmbh | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
CN104780915A (zh) | 2012-07-11 | 2015-07-15 | 埃尔舍利克斯治疗公司 | 包含他汀、双胍和用于减小心脏代谢风险的其它药剂的组合物 |
US9169205B2 (en) | 2012-10-08 | 2015-10-27 | Boehringer Ingelheim International Gmbh | Pyrrolidine derivatives, pharmaceutical compositions and uses thereof |
BR112015015250A2 (pt) * | 2013-01-25 | 2017-07-11 | Boehringer Ingelheim Int | derivados de pirrolidina, composições farmacêuticas e usos dos mesmos |
US8962641B2 (en) * | 2013-04-17 | 2015-02-24 | Boehringer Ingelheim International Gmbh | Pyrimidine-substituted pyrrolidine derivatives, pharmaceutical compositions and uses thereof |
EP2997024B1 (en) | 2013-05-17 | 2018-03-28 | Boehringer Ingelheim International GmbH | Pyrrolidine derivatives, pharmaceutical compositions and uses thereof |
CN104592120A (zh) * | 2015-02-13 | 2015-05-06 | 佛山市赛维斯医药科技有限公司 | 一种环丙基酰肼和甲氧苯类gpr119激动剂、制备方法及其用途 |
CN104892517A (zh) * | 2015-02-13 | 2015-09-09 | 佛山市赛维斯医药科技有限公司 | 酰肼类化合物、其制备方法及用途 |
CN104610151A (zh) * | 2015-02-13 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | 含酰肼和烷氧苯类结构的化合物、其制备方法及用途 |
CA3178994A1 (en) | 2020-05-19 | 2021-11-25 | Iyassu Sebhat | Ampk activators |
CN116390925A (zh) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | Ampk活化剂 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7253204B2 (en) * | 2004-03-26 | 2007-08-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
DK1756084T3 (da) * | 2004-06-04 | 2009-03-23 | Arena Pharm Inc | Substituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser beslægtet dermed |
DOP2006000010A (es) * | 2005-01-10 | 2006-07-31 | Arena Pharm Inc | Procedimiento para preparar eteres aromáticos |
MX2007016545A (es) * | 2005-06-30 | 2008-02-21 | Prosidion Ltd | Agonistas del receptor acoplado a la proteina g. |
EP1907384A2 (en) * | 2005-06-30 | 2008-04-09 | Prosidion Limited | Gpcr agonists |
GB0607196D0 (en) * | 2006-04-11 | 2006-05-17 | Prosidion Ltd | G-protein coupled receptor agonists |
-
2009
- 2009-02-20 BR BRPI0907584-4A patent/BRPI0907584A2/pt not_active IP Right Cessation
- 2009-02-20 WO PCT/US2009/034781 patent/WO2009105715A1/en active Application Filing
- 2009-02-20 MX MX2010009204A patent/MX2010009204A/es not_active Application Discontinuation
- 2009-02-20 AU AU2009217359A patent/AU2009217359B2/en not_active Ceased
- 2009-02-20 EP EP09711737A patent/EP2262496A1/en not_active Withdrawn
- 2009-02-20 US US12/918,805 patent/US20110166176A1/en not_active Abandoned
- 2009-02-20 CA CA2714703A patent/CA2714703A1/en not_active Abandoned
- 2009-02-20 JP JP2010547819A patent/JP2011513232A/ja active Pending
- 2009-02-20 EA EA201001332A patent/EA201001332A1/ru unknown
- 2009-02-20 KR KR1020107021109A patent/KR20100120689A/ko not_active Application Discontinuation
- 2009-02-20 CN CN200980113843XA patent/CN102006870A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
US20110166176A1 (en) | 2011-07-07 |
AU2009217359A1 (en) | 2009-08-27 |
WO2009105715A1 (en) | 2009-08-27 |
EA201001332A1 (ru) | 2011-04-29 |
CA2714703A1 (en) | 2009-08-27 |
CN102006870A (zh) | 2011-04-06 |
MX2010009204A (es) | 2010-11-10 |
JP2011513232A (ja) | 2011-04-28 |
EP2262496A1 (en) | 2010-12-22 |
AU2009217359B2 (en) | 2011-09-01 |
KR20100120689A (ko) | 2010-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0907584A2 (pt) | Composto e composições como moduladores de atividade de gpr119 | |
BRPI0911118A2 (pt) | composto e compisições como moduladores de atividade de gpr119 | |
BRPI0817211A2 (pt) | composto composições como moduladores da atividade de gpr119 | |
BRPI0808192A2 (pt) | composto e composições como moduladores de atividades de gpr119 | |
BRPI0915867A2 (pt) | 4-fenoximetilpiperidinas como moduladores de atividade de gpr119 | |
BRPI0909037A2 (pt) | compostos e composições como moduladores da atividade de tlr | |
BRPI0912431A2 (pt) | Combinações de substâncias ativas sinergísticas | |
BRPI0922845A2 (pt) | pirazol-4-n-alcoxicarboxamidas como microbiocidas | |
BRPI0908851A2 (pt) | compostos e composições como moduladores da atividades de gpr119 | |
SMT201300040B (it) | Analoghi piridonici e piridazonici come modulatoridi gpr119 | |
BRPI0906749A2 (pt) | Composição | |
BRPI0913808A2 (pt) | composição | |
BRPI0912668A2 (pt) | composto e composições como inibidores de quinase | |
BRPI0917017A2 (pt) | inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos | |
BRPI0914652A2 (pt) | compostos e composições como inibidores de quinase | |
DK2634232T3 (da) | Sammensætninger | |
BRPI0906973A2 (pt) | Compostos e composições como inibidores de cinase. | |
BRPI0913117A2 (pt) | imidazopiridina e análogos relacionados como moduladores de sirtuína | |
IT1392101B1 (it) | Composizione comprendente isoflavoni | |
BRPI0919708A2 (pt) | composições antimicrobianas | |
BRPI0922464A2 (pt) | Combinações de compostos ativos | |
BRPI0917231A2 (pt) | composição | |
DK2403814T3 (da) | Landbrugsmæssig sammensætning | |
BRPI0910979A2 (pt) | compostos e composições como inibidores de quinase | |
BRPI0918344A2 (pt) | composição catalítica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |